Solid vaccine protection against SIV in rhesus monkeys provides proof-of-concept for further evaluation of a novel HIV vaccine approach in humans

Expert Review of Vaccines

Volumn 11, Issue 5, 2012, Pages 539-542

  Esparza, José ^a  

^a BILL AND MELINDA GATES FOUNDATION   (United States)

Author keywords

antibodies; correlates of protection; HIV; nonhuman primate model; SIV; vaccine

Indexed keywords

GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PARVOVIRUS VECTOR; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS ENVELOPE PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIGEN BINDING; CELLULAR IMMUNITY; CORRELATION ANALYSIS; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHESUS MONKEY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS LOAD; VIRUS NEUTRALIZATION;

EID: 84862512814     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.12.21     Document Type: Note

References (17)

1. Barouch DH, Liu J, Li H et al. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 482(7383), 89-93 (2012
2. Esparza J, Russell N, Gayle H et al. The challenge of developing an HIV vaccine. In: HIV Vaccine Research and Development in Thailand. Pitisuttithum P, Francis DP, Esparza J et al. (Eds). Mahidol University, Bangkok, Thailand, 3-26 (2006
3. Barouch DH. Challenges in the development of an HIV-1 vaccine. Nature 455(7213), 613-619 (2008
4. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF; rgp120 HIV Vaccine Study Group. Placebocontrolled Phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J. Infect. Dis. 191(5), 654-665 (2005
5. Pitisuttithum P, Gilbert P, Gurwith M et al.; Bangkok Vaccine Evaluation Group. Randomized, double-blind, placebocontrolled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J. Infect. Dis. 194(12), 1661-1671 (2006
6. Freel SA, Saunders KO, Tomaras GD. CD8+ T-cell-mediated control of HIV-1 and SIV infection. Immunol. Res. 49(1-3), 135-146 (2011
7. Buchbinder SP, Mehrotra DV, Duerr A et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372(9653), 1881-1893 (2008
8. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S et al.; MOPH-TAVEG Investigators. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361(23), 2209-2220 (2009
9. Haynes BF, Gilbert PB, McElrath MJ et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366(14), 1275-1280 (2012
10. Johnston MI, Fauci AS. An HIV vaccine - evolving concepts. N. Engl. J. Med. 356(20), 2073-2081 (2007
11. Burton DR, Desrosiers RC, Doms RW et al. Public health. A sound rationale needed for Phase III HIV-1 vaccine trials. Science 303(5656), 316 (2004
12. Letvin NL, Rao SS, Montefiori DC et al. Immune and genetic correlates of vaccine protection against mucosal infection by SIV in monkeys. Sci. Transl. Med. 3(81), 81ra36 (2011
13. Keele BF, Li H, Learn GH et al. Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. J. Exp. Med. 206(5), 1117-1134 (2009
14. Kwong PD, Mascola JR, Nabel GJ. Rational Design of Vaccines to Elicit Broadly Neutralizing Antibodies to HIV-1. Cold Spring Harb. Perspect. Med. 1(1), a007278 (2011
15. DeVico A, Fouts T, Lewis GK et al. Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogens. Proc. Natl Acad. Sci. USA 104(44), 17477-17482 (2007
16. Sun Y, Asmal M, Lane S et al. Antibodydependent cell-mediated cytotoxicity in simian immunodeficiency virus-infected rhesus monkeys. J. Virol. 85(14), 6906-6912 (2011
17. Walker BD, Ahmed R, Plotkin S. Use both arms to beat HIV. Nature Med. 17(10), 1194-1195 (2011)